sorafenib has been researched along with navitoclax in 3 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (navitoclax) | Trials (navitoclax) | Recent Studies (post-2010) (navitoclax) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 429 | 15 | 401 |
| Protein | Taxonomy | sorafenib (IC50) | navitoclax (IC50) |
|---|---|---|---|
| Bcl-2-like protein 11 | Homo sapiens (human) | 0.0043 | |
| Apoptosis regulator Bcl-2 | Homo sapiens (human) | 0.0091 | |
| Bcl-2-like protein 1 | Homo sapiens (human) | 0.0168 | |
| Aspartyl/asparaginyl beta-hydroxylase | Homo sapiens (human) | 1.0925 | |
| Bcl-2-like protein 2 | Homo sapiens (human) | 0.07 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Giaccone, G; Killian, KJ; Lee, C; Lee, HS; Luo, J; Meltzer, PS; Petrini, I; Roncalli, M; Santoro, A; Steinberg, SM; Tsokos, M; Wang, Y; Zucali, PA | 1 |
| Chen, Y; Li, J; Li, W; Liu, X; Wan, J; Yu, C | 1 |
3 other study(ies) available for sorafenib and navitoclax
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Aniline Compounds; Animals; Apoptosis Regulatory Proteins; Autophagy; bcl-X Protein; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Comparative Genomic Hybridization; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; DNA Copy Number Variations; Female; Humans; Indoles; Male; Mice; Mice, Nude; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms, Glandular and Epithelial; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Pyrroles; RNA Interference; RNA, Small Interfering; Sorafenib; Sulfonamides; Thymus Neoplasms; TOR Serine-Threonine Kinases; Transplantation, Heterologous | 2012 |
ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells.
Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |